Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MorphoSys Fills Out Pipeline With Xencor Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.

You may also be interested in...

Morphosys Seeks US Listing To Cement Corporate Developments

German biotech Morphosys has filed an F-1 registration statement with the US Securities & Exchange Commission to list the ADSs on the Nasdaq Global Market to raise its profile among US investors and raise up to $150m. Funds will primarily be used to support the company’s ambitions to commercialize MOR208 in the US.

MorphoSys CEO Says Strategy To Build Proprietary Pipeline 'On Track'

MorphoSys CEO Simon Moroney tells Scrip that sales of Tremfya in the US and now Europe as a treatment for plaque psoriasis will help fund the German biotech's nascent proprietary pipeline.

MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans

MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts